Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
67%(4 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_3
2
14%
Ph phase_2
4
29%
Ph phase_4
4
29%
Ph phase_1
1
7%
Ph not_applicable
3
21%

Phase Distribution

1

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
4(28.6%)
N/ANon-phased studies
3(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)
Other(5)

Detailed Status

Completed6
unknown5
Enrolling by invitation1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 24 (28.6%)
Phase 32 (14.3%)
Phase 44 (28.6%)
N/A3 (21.4%)

Trials by Status

unknown536%
enrolling_by_invitation17%
completed643%
terminated17%
withdrawn17%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14